Activation of PPARγ in myeloid cells promotes lung cancer progression and metastasis

OncoImmunology

Volumn 1, Issue 3, 2012, Pages 403-404

  Nemenoff, Raphael ^a  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

Author keywords

Inflammation; Lung cancer; Macrophages; Metastasis; PPAR ; Progression

Indexed keywords

GLITAZONE DERIVATIVE; ILOPROST; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PIOGLITAZONE; ROSIGLITAZONE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE MARROW CELL; BRAIN METASTASIS; CANCER GROWTH; CANCER INHIBITION; DIABETES MELLITUS; DRUG TARGETING; HUMAN; LIVER CELL CARCINOMA; LUNG CANCER; MACROPHAGE; METASTASIS; NONHUMAN; PRIORITY JOURNAL; TUMOR MICROENVIRONMENT; TUMOR PROMOTION;

EID: 84871668861     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.4161/onci.19309     Document Type: Article

References (10)

1. Maeda S, Kamata H, Luo JL, Leffert H, Karin M. IKKbeta couples hepatocyte death to cytokine-driven compensatory proliferation that promotes chemical hepatocarcinogenesis. Cell 2005; 121:977-90; http://dx.doi.org/10.1016/j.cell.2005.04.014
2. Govindarajan R, Ratnasinghe L, Simmons DL, Siegel ER, Midathada MV, Kim L, et al. Thiazolidinediones and the risk of lung, prostate, and colon cancer in patients with diabetes. J Clin Oncol 2007; 25:1476-81; http://dx.doi.org/10.1200/JCO.2006.07.2777
3. Bren-Mattison Y, Meyer AM, Van Putten V, Li H, Kuhn K, Stearman R, et al. Antitumorigenic effects of peroxisome proliferator-activated receptor-gamma in non-small-cell lung cancer cells are mediated by suppression of cyclooxygenase-2 via inhibition of nuclear factor-kappaB. Mol Pharmacol 2008; 73:709-17; http://dx.doi.org/10.1124/mol.107.042002
4. Li H, Sorenson AL, Poczobutt J, Amin J, Joyal T, Sullivan T, et al. Activation of PPARc in Myeloid Cells Promotes Lung Cancer Progression and Metastasis. PLoS One 2011; 6:e28133; http:// dx.doi.org/10.1371/journal.pone.0028133
5. Allavena P, Sica A, Solinas G, Porta C, Mantovani A. The inflammatory micro-environment in tumor progression: the role of tumor-associated macrophages. Crit Rev Oncol Hematol 2008; 66:1-9; http:// dx.doi.org/10.1016/j.critrevonc.2007.07.004
6. Bouhlel MA, Derudas B, Rigamonti E, Dièvart R, Brozek J, Haulon S, et al. PPARgamma activation primes human monocytes into alternative M2 macrophages with anti-inflammatory properties. Cell Metab 2007; 6:137-43; http://dx.doi.org/10.1016/j.cmet.2007.06.010
7. Dai F, Liu L, Che G, Yu N, Pu Q, Zhang S, et al. The number and microlocalization of tumor-associated immune cells are associated with patient's survival time in non-small cell lung cancer. BMC Cancer 2010; 10:220; http://dx.doi.org/10.1186/1471-2407-10-220
8. Condeelis J, Pollard JW. Macrophages: obligate partners for tumor cell migration, invasion, and metastasis. Cell 2006; 124:263-6; http://dx.doi.org/10.1016/j.cell.2006.01.007
9. Tennis MA, Van Scoyk M, Heasley LE, Vandervest K, Weiser-Evans M, Freeman S, et al. Prostacyclin inhibits non-small cell lung cancer growth by a frizzled 9-dependent pathway that is blocked by secreted frizzled-related protein 1. Neoplasia 2010; 12:244-53;
10. Künzli BM, Bernlochner MI, Rath S, Käser S, Csizmadia E, Enjyoji K, et al. Impact of CD39 and purinergic signalling on the growth and metastasis of colorectal cancer. Purinergic Signal 2011; 7:231-41; http://dx.doi.org/10.1007/s11302-011-9228-9